skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients

Review

(2172) Views  (701) Full article downloads

Authors: Barbara Błaszczyk, Stanisław J Czuczwar

Published Date April 2010 Volume 2010:6(1) Pages 145 - 150
DOI: http://dx.doi.org/10.2147/NDT.S6515

Barbara Błaszczyk1,2, Stanisław J Czuczwar3,4

1Department of Neurology, Neuropsychiatric Hospital, Kielce, Poland; 2Faculty of Health Sciences, High School of Economics and Law, Kielce, Poland; 3Department of Pathophysiology, Medical University, Lublin, Poland; 4Department of Physiopathology, Institute of Agricultural Medicine, Lublin, Poland

Abstract: Epilepsy is a frequent, chronic disease demanding long-term medication with antiepileptic drugs (AEDs). When slow release formulations of AEDs are used the chance of compliance and control of seizures is increased. Lamotrigine (LTG) is a broad spectrum antiepileptic drug (AED), effective against both generalized and partial seizures. Its immediate-release formulation (LTG-IR) requires twice-daily dosing. In contrast, an extended-release formulation (LTG-XR) may be given once daily, providing a flatter dose-concentration curve with apparently lower maximum serum levels. Simplified dosing positively affects compliance and LTG-XR has a similar profile of efficacy and tolerability to LTG-IR. Rashes, including Stevens–Johnson syndrome, are the most serious adverse effect impacting 0.8% of pediatric patients. Thus, LTG-XR should be discontinued upon the appearance of rash.

Keywords: epilepsy, antiepileptic drugs, extended-release, lamotrigine, adverse reactions, tolerability, pharmacokinetics






 

Other articles by Professor Stanislaw Czuczwar



Readers of this article also read:

The role of lamotrigine in the management of bipolar disorder
Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran
Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release
Current trends in the treatment of infantile spasms
Bactericidal effects of silver plus titanium dioxide-coated endotracheal tubes on Pseudomonas aeruginosa and Staphylococcus aureus
Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes
Congenital chloride diarrhea: late presentation
A descriptive analysis of drug treatment patterns and burden of illness for pediatric patients diagnosed with partial-onset seizures in the USA
Clinical utility of adjunctive retigabine in partial onset seizures in adults